Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hana Biosciences Prepares To Submit First Ondansetron Oral Spray

This article was originally published in The Pink Sheet Daily

Executive Summary

Pivotal trials confirm Zensana spray is bioequivalent to Zofran tablets for chemotherapy induced nausea and vomiting.

You may also be interested in...



Ondansetron Oral Spray Could Launch In H1 07

Hana Biosciences' ondansetron oral spray Zensana has an estimated user fee date at the end of April

Ondansetron Oral Spray Could Launch In H1 07

Hana Biosciences' ondansetron oral spray Zensana has an estimated user fee date at the end of April

FDA Rescinds Zofran ODT ANDA Approval

A prior court decision that Par's ondansetron infringes an unexpired GSK patent prompts FDA to revoke approval.

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel